ILT3 binding molecules and uses therefor
US8901281B2 · kind B2 · utility
10Cited by
43References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 19, 2006 |
| Grant date | Dec 2, 2014 |
| Priority date | — |
| Expiry date | Jun 19, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof. Methods of using the binding molecules of the invention to detect human ILT3 or to modulate human ILT3 activity, either in vitro or in vivo, are also encompassed by the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.